Overview

Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to gather information on the combination Zetia® (Ezetimibe) and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty liver disease (NAFLD).
Phase:
Phase 2
Details
Lead Sponsor:
Gregory Graf, PhD
Treatments:
Ezetimibe
Ursodeoxycholic Acid